1. Al-Hashmi, S., Hassan, Z., Sadeghi, B., Rozell, B., Hassan, M., 2011. Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen. Int. J. Clin. Exp. Pathol., 4(6):596–605.
2. Barrett-Connor, E., Stuenkel, C., 1999. Hormones and heart disease in women: heart and estrogen/progestin replacement study in perspective. J. Clin. Endocrinol. Metab., 84(6):1848–1853. [doi:10.1210/jc.84.6.1848]
3. Benedict, J.C., Lin, T.M., Loeffler, I.K., Peterson, R.E., Flaws, J.A., 2000. Physiological role of the aryl hydrocarbon receptor in mouse ovary development. Toxicol. Sci., 56(2):382–388. [doi:10.1093/toxsci/56.2.382]
4. Burkl, W., Schiechl, H., 1978. The growth of follicles in the rat ovary under the influence of busulphan and endoxan. Cell Tissue Res., 186(2):351–359. [doi:10.1007/BF00225543]
5. Copelan, E.A., Biggs, J.C., Szer, J., Thompson, J.M., Crilley, P., Brodsky, I., Klein, J.L., Kapoor, N., Harman, G.S., Avalos, B.R., 1993. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2). Semin. Oncol., 20(Suppl. 4):33–38.